John O. Watson, PhD (Panvera)
David Monteith, PhD (Eli Lilly)
James Grace, PhD (Eli Lilly)

May 28, 2003
Noon - 1:30 pm (EST)

High throughput ADMETox assays permit efficient prioritization of drug lead candidates. Most large pharmaceutical companies now routinely screen leads for in vitro toxicity and cytochrome p450 inhibition in order to minimize potential toxicity events later in drug development. Some companies are even doing total library screens in order to generate structure-activity-relationship data around particular drug backbones. The success of these screening efforts has led to the development of other assays such as drug transporter assays, Herg channel assays and mircoarray assays. This seminar will look at what the current state of the art is, look at technologies that are just being implemented and those are likely to be important in the future.

At the conclusion of the High-throughput ADMETox Drug Screening Virtual Seminar, attendees will be able to:

• Appreciate the importance of conducting ADME/Tox studies early in the drug discovery process.
• Understand the current level of technology and research being conducted in the AMDE/Tox field.
• Relate the newest technologies and assays to their current research, and be able to plan for advances in the future.
• Preview the cutting edge technologies and products that are on the horizon in the ADME/Tox arena.
• Increase understanding of industry liquid handling needs.

Questions?
Check the FAQ